Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report

Vasiliki Vasileiou; Stavroula A Paschou; Xakousti Tzamali; Marina Mitropoulou; Fotini Kanouta; Theodora Psaltopoulou; Georgia N Kassi

doi:10.1016/j.crwh.2021.e00378

Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report

Case Rep Womens Health. 2022 Jan:33:e00378. doi: 10.1016/j.crwh.2021.e00378. Epub 2021 Dec 28.

Authors

Vasiliki Vasileiou¹, Stavroula A Paschou², Xakousti Tzamali¹, Marina Mitropoulou¹, Fotini Kanouta¹, Theodora Psaltopoulou³, Georgia N Kassi¹

Affiliations

¹ Department of Endocrinology, Alexandra Hospital, Athens, Greece.
² Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
³ Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

SARS-CoV-2 vaccination is the most powerful and promising tool against the COVID-19 pandemic. Millions of people have been vaccinated worldwide. Recently, few cases of subacute thyroiditis following SARS-CoV-2 vaccination with various types of vaccine have been reported. We describe here a 36-year-old woman who presented with subacute thyroiditis 10 days after she had received her first dose of the SARS-CoV-2 mRNA vaccine Comirnaty (Pfizer/BioNTech); the condition receded but then recurred 10 days after she received her second dose. As vaccination programmes proceed, clinicians' attention and vigilance for such cases will be increased. Physicians need to know that subacute thyroiditis is a mild and self-limiting condition in the majority of cases. Last but not least, the benefits of vaccination against COVID-19 outweigh the side-effects reported so far.

Keywords: COVID-19; SARS-CoV-2; Thyroiditis; Vaccination; mRNA vaccine.

Publication types

Case Reports